Krystal Biotech (NASDAQ: KRYS) — Company Overview, News & Financial Data
Krystal Biotech develops gene therapies for serious skin diseases, aiming to improve treatment for dermatological conditions.
Krystal Biotech
Krystal Biotech is a commercial-stage biotechnology company focused on discovering, developing, and commercializing redosable gene therapies for patients with rare and severe genetic diseases. The company utilizes a proprietary HSV-1 viral vector platform engineered to deliver functional genes directly to targeted cells without integrating into the host genome. Its lead commercial product, VYJUVEK, is approved for the treatment of dystrophic epidermolysis bullosa. Krystal Biotech operates in-house Good Manufacturing Practice facilities in Pittsburgh, Pennsylvania, to support commercial production and clinical development. Its broader research and clinical pipeline addresses debilitating dermatological, respiratory, and ophthalmological conditions.
Snapshot
Operations
Products and/or services of Krystal Biotech
- Approved Gene Therapies: Commercialization of topical herpes simplex virus type 1-based redosable gene therapy for the treatment of dystrophic epidermolysis bullosa across commercial markets including the United States, Europe, and Japan.
- Dermatological Gene Therapies: Development and clinical evaluation of redosable gene therapy candidates targeting rare skin disorders, including investigational therapeutics engineered to deliver missing structural proteins to patients with severe inherited dermatological conditions.
- Ophthalmology Pipeline: Preclinical and clinical development of redosable gene therapies formulated as eye drops to deliver therapeutic genes directly to ocular surface tissues for treating rare genetic corneal and anterior segment diseases.
- Respiratory Pipeline: Development of aerosolized inhaled gene therapy formulations engineered to deliver functional genes to airway epithelial cells for the treatment of cystic fibrosis and other genetic pulmonary conditions.
- Engineered HSV-1 Platform: Research and engineering of replication-deficient, non-integrating herpes simplex virus type 1 viral vectors designed for repeated topical, ocular, or inhaled delivery of large or multiple human genes.
- In-House Manufacturing Operations: Operation of two commercial and clinical Good Manufacturing Practice facilities in Pittsburgh, Pennsylvania, providing end-to-end production, quality control, and supply chain management for viral vector drug products.
Krystal Biotech executive team
- Krish S. KrishnanFounder, Chairman, President & CEO
- Suma M. KrishnanFounder, President of R&D and Director
- Kathryn A. RomanoExecutive VP & Chief Accounting Officer
- John C. ThomasEVP, General Counsel & Corporate Secretary
- John KarakkalVice President of North American Sales & Marketing
- Stephane PaquetteSenior Vice President of Corporate Development
- Josh SuskinSenior Director & Head of US Human Resources
- Laurent GouxExecutive VP & Head of International
- David ChienSenior Vice President of Clinical Development
- Christine WilsonSenior VP & Head of US Commercial
Key financials
Reported results for Krystal Biotech, in USD.
- Market cap
- 9B
- Revenue (TTM)
- 470M
- P/E ratio
- 41.4
- EPS (diluted, TTM)
- 7.4
- Dividend yield
- —
- Profit margin
- 47.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 389.1M | 161.3M | 204.8M | |
| 290.5M | 65.7M | 89.2M | |
| 50.7M | -109.7M | 10.9M | |
| 0 | -145.2M | -140M |